BidaskClub lowered shares of Inogen (NASDAQ:INGN) from a hold rating to a sell rating in a research report report published on Saturday.

INGN has been the subject of several other research reports. Needham & Company LLC increased their target price on shares of Inogen from $108.00 to $125.00 and gave the company a strong-buy rating in a report on Wednesday, November 8th. Piper Jaffray Companies reiterated a hold rating and issued a $90.00 target price on shares of Inogen in a report on Tuesday, September 12th. Zacks Investment Research upgraded shares of Inogen from a hold rating to a buy rating and set a $131.00 target price for the company in a report on Thursday, November 9th. Finally, Leerink Swann reiterated an outperform rating and issued a $120.00 target price (up previously from $115.00) on shares of Inogen in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $103.14.

Shares of Inogen (NASDAQ INGN) traded down $5.60 during mid-day trading on Friday, hitting $114.25. 363,000 shares of the stock traded hands, compared to its average volume of 178,660. The stock has a market capitalization of $2,370.00, a P/E ratio of 79.90, a P/E/G ratio of 4.06 and a beta of 1.13. Inogen has a 52 week low of $62.69 and a 52 week high of $130.05.

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.04. The company had revenue of $69.00 million during the quarter, compared to the consensus estimate of $63.55 million. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The firm’s revenue for the quarter was up 26.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.25 earnings per share. analysts forecast that Inogen will post 1.19 EPS for the current year.

In related news, EVP Byron Myers sold 35,000 shares of the firm’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $116.77, for a total transaction of $4,086,950.00. Following the completion of the sale, the executive vice president now owns 48,600 shares in the company, valued at $5,675,022. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ray Benjamin M. Anderson sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $119.06, for a total transaction of $119,060.00. Following the sale, the director now owns 1,000 shares of the company’s stock, valued at approximately $119,060. The disclosure for this sale can be found here. Insiders have sold 84,000 shares of company stock valued at $9,502,395 in the last 90 days. 5.31% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in Inogen by 1.9% during the second quarter. BlackRock Inc. now owns 2,150,552 shares of the medical technology company’s stock worth $205,207,000 after buying an additional 39,752 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Inogen by 24.9% in the second quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock worth $144,594,000 after purchasing an additional 301,737 shares in the last quarter. Koch Industries Inc. increased its stake in shares of Inogen by 19,485.8% in the second quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock worth $650,000 after purchasing an additional 653,747 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Inogen by 3.4% in the second quarter. Dimensional Fund Advisors LP now owns 519,523 shares of the medical technology company’s stock worth $49,572,000 after purchasing an additional 17,111 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Inogen by 6.8% in the second quarter. State Street Corp now owns 425,662 shares of the medical technology company’s stock worth $40,619,000 after purchasing an additional 27,250 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “Inogen (INGN) Cut to “Sell” at BidaskClub” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2018/01/09/inogen-ingn-cut-to-sell-at-bidaskclub.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Stock Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related stocks with our FREE daily email newsletter.